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Abstract 
 
Ibrahim, Ayon  Investigating the Use of Aptamers in Binding to the Human Follicle Stimulating 
Hormone Receptor (hFSHR). Department of Biological Sciences, June 2013. 
 
Advisor: Brian D. Cohen 
 
 
 Oral contraceptive pills use high doses of hormone to suppress the reproductive arm of the 
endocrine system in women.  However, these drugs can have harmful long term side effects such as 
increased risk of stroke, heart attack, and breast cancer.  Therefore, it has become an important public 
health goal to look for alternative ways of providing contraception. Aptamers, oligonucleotides that 
bind to specific molecules due to their unique 3-dimensional structure, are one alternative that has yet 
to be explored. The goal of our research is to develop an RNA aptamer that will bind selectively to the 
hFSHR. We first incubated a large pool containing random sequence oligonucleotides with wild type 
HEK293 cells (which do not have hFSHR) as a counter-selection. Many of the RNA molecules bound 
to the protein receptors on the cell surface. The unbound molecules were then incubated with HEK293 
cells expressing the hFSHR. The oligonucleotides that bound to the hFSHR were eluted, isolated, and 
then re-amplified. The process of selection was repeated while increasing stringency of binding each 
time. We were able to successfully perform SELEX on our RNA pool at 4°C and 22°C. We also 
conducted nanodrop experiments to confirm that our oligonucleotides are indeed binding specifically to 
the hFSHR. We hope to continue refining our aptamer at higher temperatures such as 30°C and 37°C, 
determine the exact nature of the oligonucleotide-protein binding complex, and eventually begin in vivo 
trials to determine efficacy.  
 
Introduction 
 
 The human follicle-stimulating hormone (FSH), also called follitropin, is a glycoprotein 
secreted by the basophil cells in the anterior pituitary gland. It is a dimeric protein, consisting of an 
alpha and a beta subunit, the latter of which interacts with the FSH receptor (FSHR). It is primarily the 
pulsatile release of gonadotropin releasing hormone (GnRH), from the arctuate nucleus of the medial 
basal hypothalamus, that causes the production and release of FSH from the gonadotropic cells of the 
anterior pituitary.  In males, follitropin binds to Sertoli cells in the testes, which induces the release of 
inhibin, a protein hormone that negatively feed backs on the gonadotropes in the pituitary gland and 
decreases the synthesis of follitropin, and activin, which also stimulates FSH production, in addition to 
aromatase production and spermatogenesis [1]. A third hormone, follistatin, works with inhibin by 
suppressing FSH gene expression. In females, follitropin binds to granulosa cells in ovaries, stimulating 
the release of inhibin, as it does in the male. It also stimulates the production and release of 
estrogen/estradiol, a steroid hormone that not only increases GnRH pulses from the hypothalamus but 
also binds to the anterior pituitary and inhibits FSH production and release. Estrogen is crucial for 
development of bone, muscle and secondary sex characteristics in the female [2]. Progesterone, a 
steroid hormone released by theca cells in the ovary, acts upon the hypothalamus to lower GnRH 
pulses. Progesterone's release is regulated by luteinizing hormone (LH), a dimeric protein similar in 
structure to FSH that is also released by the basophil cells of the anterior pituitary. In the male, LH also 
stimulates the release of testosterone which, decreases GnRH pulses and promotes growth of muscle, 
bone and secondary sex organs. [1][3].  
 FSH is essential for the proper reproductive development in both sexes. In males, follitropin 
promotes spermatogenesis and stimulates primary spermatocytes to undergo meiosis. In females, FSH 
is crucial for developing and sustaining ovarian foll icles through the activation of over 100 different 
genes, all of which leads to multiple physical changes such as increased vascularization of the theca 
interna layer of cells near the basal lamina and formation of a fluid-filled antrum within the growing 
follicular cell [1]. FSH effectively prepares the uterus for implantation of a fertilized egg [2]. As levels 
of inhibin increase, FSH levels decrease and remain low until the end of the luteal phase, the latter 
stage of menstruation, in which a renewed, steady rise in FSH prepares more follicular cells for the 
next ovulatory cycle [2][3].  
 Oral contraception works by interrupting the FSH signaling pathway: the pills contain estrogen 
and/or progesterone. As mentioned above, high levels of progesterone negatively feeds back on the 
hypothalamus, causing a decrease in the amount of gonadotropin releasing hormone (GnRH), which in 
turn results in a decrease in the release of FSH and LH by the anterior pituitary. Also, high levels of 
estrogen negatively feeds back on the anterior pituitary gland and inhibit the release of FSH [3]. The 
presence of oral contraceptives thus prevents proper reproductive maturation by inhibiting the release 
of FSH and LH, which cause the ovary cells to undergo atresia and therefore suppress the chance of 
successful ovulation [4].  
 However, studies have shown that inducing unnaturally elevated levels of estrogen and 
progesterone by consuming these pills have dangerous side effects. For example, a 2010 paper 
published in the Expert Review of Cardiovascular Therapy journal showed that usage of the combined 
hormonal oral contraceptive had significant correlations with an increased risk in venous 
thromboembolism, which is the formation of blood clots in veins, commonly in the leg or pelvic area 
[4]. A meta-analysis of several studies have shown similar results in that women taking second 
generation oral contraceptives (containing less than 50 ?g of estrogen) have a significantly higher risk 
of both myocardial infarction and ischemic stroke. Third generation contraceptives are associated with 
a high risk of vascular arterial complications, especially with women of older age [5]. Additional 
research supports the conclusion that usage of certain oral contraceptives (such as desogestrel and 
gestodene) is associated with higher risk of ischemic stroke, deep vein thrombosis and cardiovascular 
disease [6]. However, it is not just the cardiovascular system that is impacted negatively by the 
consumption of oral contraceptives. An in-depth study has revealed that both perimenopausal and 
postmenopausal women who take oral contraceptives on a chronic basis increases their risks of breast, 
cervical and liver cancer in addition to ischemic stroke. The risk was observed to be greater when the 
women took the combined estrogen-progesterone pills as compared to estrogen alone. However, the 
same study showed that there can also be multiple beneficial side effects, such as decreased risk of 
ovarian and endometrial cancer, pelvic inflammatory disease (PID) and colorectal cancer [7]. Another 
study showed that high levels of estrogen sustained for over 21 days lead to abnormally high levels of 
plasma cortisol and tryptophan, as well as high levels of tryptophan metabolites in urine. The 
researchers suggest that these elevated tryptophan levels may be related to mental depression and/or 
rheumatoid arthritis, though the mechanisms remain uncertain. They also postulate that the higher 
cortisol levels as a result of the oral contraceptive pills led to the liver being exposed to high 
glucocorticoid concentrations, which led to the finding of impaired glucose tolerance in 75% of the 
women, while 13% developed diabetes mellitus [8]. Finally, one comprehensive study provides 
evidence that estrogen/progesterone pills have little to no effect on the risk of developing breast cancer, 
contradictory to what other studies have shown [9]. Clearly, these pills have an intricate and complex 
range of effects on the human body, much of which is not completely understood. 
Another possible contraceptive option is called the intrauterine device (IUD), which works by 
inserting a T-shaped object into the uterus, inducing a localized inflammatory reaction in the 
endometrium, causing a release of the of endometrium's cellular and humoral components. 
Additionally, some IUD's, such as Cu-IUD's, release ions such as copper into the uterine cavity, which 
can reach concentrations toxic to sperm and/or developing zygotes [10]. IUD's have higher success 
rates for preventing pregnancy than do hormonal pills, but have also been known to cause heavier 
bleeding or more painful menstrual cramps [3][3.5]. There is one possible method of contraception that 
has not been explored, but may have a high chance of success without harmful side effects, and that is 
blocking the FSHR directly.    
 The FSHR belongs to a class of large molecules called G-protein coupled receptors which are 
embedded in the cell membrane. They have a 7-alpha helical transmembrane spanning domain (TM 
domain) and a glycosylated extracellular domain (ECD). They are highly prolific in mammal granulosa 
cells: those from rats are reported to have around 4,600 receptors per cell. It is worthy to note here that 
this protein, in particular the TM domain, is highly conserved among animal species, especially 
mammals, with the most variation in the C-terminal tail [1]. Glycosylation of the ECD is also highly 
conserved. Thus, research done on rat FSHR is highly applicable to human FSHR. Binding of FSH to 
the ECD of the receptor causes a shift in conformation and activation of the G-protein at the C-
terminus on the intracellular side of the membrane. This action causes adenlyl cyclase to convert ATP 
to cAMP, beginning a very complex protein signaling pathway illustrated in Figure 1 that eventually 
leads to gene expression [2]. An important step in the signaling pathway is the activation of protein 
kinase A (PKA), a necessary action for the directing of granulosa cell differentiation, as signals from 
cAMP are mainly mediated through PKA. For example, PKA regulates the activity of the transcription 
factor cAMP response element binding protein (CREB) and protein kinase p38 MAPK, two different 
signaling pathways that contribute to follicular maturation. As can be seen on Figure 1, there is another 
signaling pathway that is activated by calcium ion movement (with some unknown protein regulating 
that activity) rather than by FSH binding. However, even this pathway is eventually influenced by 
FSHR activity, as one of its proteins, PTP/ERK, is phosphorylated by PKA [2]. The importance of the 
FSHR in proper reproductive development is further shown by the low occurrences of natural 
mutations, as such errors would result in lower fertility and inability of the organism to pass down the 
mutated genes. This is evidenced by the A172V mutation in the ECD domain, something found among 
a sub-population in Finland, associated with hypergonadotropic ovarian dysgenesis. Many victims 
presented with infertily, amenorrhea, stunted follicular maturation, and variable secondary sex 
characteristics [11]. Therefore, it is reasonable to conclude that if a female were to use a form of 
contraception that blocked FSH binding to its receptor, the follicles would be unable to mature properly 
and ovulate.  
 
Figure 1. The protein signaling pathways found in human ovary granulosa cells. FSH plays a major role in regulating these 
pathways. Taken from Hunzicker-Dunn and Miazels (2006). 
 However, it is important to note a major drawback to this strategy. Though blocking the FSHR 
may prove to be an effective method of preventing pregnancy, it also causes a decrease or even a halt in 
the production of estrogen, which is important for many others functions in addition to reproductive 
ones, as mentioned earlier [2]. In order to have normal physiological growth and function while taking 
this form of birth control, the female would need to take estrogen supplements, which is essentially the 
same issue with consuming oral contraceptives. However, it is possible that blocking the FSHR can 
function as a safe form of male birth control. Blocking the FSHR in males will decrease 
spermatogensis, but will not affect testosterone production and secretion, as that is regulated by LH 
binding [2]. This allows for normal, healthy growth in the male while stunting fertility.  
 Another possible area of interest concerning the blocking of FSHR is animal sterilization. The 
Michaelson Prize & Grants Foundation offers a $25 million prize for the first, one-shot non-surgical 
sterilization of cats and dogs, in order to combat the high rates of euthanasia found in pet shelters 
countrywide [12]. As mentioned earlier, the FSHR is a highly conserved protein, and this fact holds 
true between humans, cats and dogs [Figure 2]. 88.33% of the amino acids in the extracellular region of 
the FSHR protein are exactly the same between the three species, and only 3.06% are completely 
different [Table 1]. Blocking the FSHR with a molecule that was specifically toxic to the reproductive 
cells it was binding to holds potential as a possible one-shot, chemical sterilization. Thus we propose 
the usage of aptamers as a novel substitute for traditional oral contraceptives and as a potential 
sterilization technique in cats and dogs.   
Table 1. A quantified comparison of the amino acid similarities and dissimilarities between human, cat and dog FSHR (360 
amino acid long extracellular region). “Identity” indicates amino acids that are exactly the same between the three species. 
 Number of Amino Acids Percentage (%) 
Identity 318 88.33 
Strongly Similar 28 7.78 
Weakly Similar 3 0.83 
Different 11 3.06 
Figure 2. The sequences for the cat, dog, and human FSHR protein (specifically the 360 amino acid long extracellular 
binding domain). An asterik (*) indicates an exact match between the three species', a colon (:) indicates strong similarity, a 
period (.) indicates weak similarity and absence of a mark indicates a major amino acid difference.  
 
 Nucleic acids (namely, RNA and DNA) have generally been associated with the storage of 
genetic information. However, their ability to form complex three-dimensional structures have raised 
interesting possibilities, as this causes the oligonucleotides to exhibit specific intermolecular forces that 
may bind to a ligand of interest, such as an enzyme's catalytic domain. They have the potential of 
becoming very important tools in the science of molecular recognition, a field in which antibodies have 
long held reign, since before the 1950's [13]. However, the usage of aptamers offers several advantages 
over the usage of antibodies as molecular sensing probes. Because the aptamer selection process is 
done in vitro, researchers have much greater control over the non-physiological conditions that can be 
used to strengthen their binding, such as salt concentration, pH, and temperature. Antibodies require an 
animal host, which in itself presents greater difficulties as the molecule of interest may be toxic to the 
organism or have little inherent immunogenic response [13][14].  Additionally, they are much more 
stable than antibodies due to the rigidity of the phosphodiester backbone. High temperatures, harsh pH 
conditions or drastically high levels of salt would irreversibly denature antibody proteins, while a RNA 
or DNA aptamer would merely unfold temporarily. In fact, because antibody markers can only be 
produced in vivo, they are restricted to physiological conditions, which means the kinetic parameters of 
their interactions with target molecules cannot be modified. Finally, due to the protein nature of 
antibodies, they cannot be stored for a long time, as they will gradually degrade. On the other hand, 
aptamers have a longer shelf life, as oligonucleotide structures tend to be very stable [11][12].  
 The in vitro method of selection used to make specific aptamers is called the systematic 
evolution of ligands by exponential enrichment (SELEX), as illustrated in Figure 3 [15]. It begins with 
the synthesis of a vast library of oligonucleotides (RNA, ssDNA, or dsDNA) that have randomized 
sequences with fixed ends for primer binding during PCR amplification. After PCR, transcription may 
be done to get RNA back, if necessary. These oligonucleotides are then incubated with the target 
molecules. Some of these randomized strands will have a greater affinity for binding than others due to 
the specific Watson-Crick pairing, non-standard base pairing and novel interactions due to unique three 
dimensional structures, such as clover shapes and loops and bent “lollipops”[15][16][18]. The more 
strongly bound oligonucleotides are isolated and amplified by PCR. These eluted molecules are subject 
to several more rounds of binding under more stringent conditions, such as increased wash time, higher 
pH, or higher temperature. The oligonucleotides that remain after multiple cycles bind very strongly to 
the target ligand. They are then isolated, cloned and analyzed [15].  
Figure 3. The SELEX process as shown in a flowchart form. Taken from Nieuwlandt (2000).  
 There exists a more specific form of aptamer selection called cell-SELEX that targets entire 
cells or ligands bound to cells as opposed to free-floating molecules. The procedure is very similar to 
normal SELEX, though often with the additional step of counter-selection. As shown in Figure 4, cell- 
SELEX starts in the expected fashion: a randomized oligonucleotide library is incubated with the target 
cells, and the bound oligonucleotides are eluted [16]. At this point, the researcher employs the counter-
selection technique, in which the eluted molecules are incubated with non-target cells (referred to as 
negative cells), after which the supernatant containing unbound oligonucleotides is collected and the 
bound aptamer-negative cells are discarded. The unbound oligonucleotides are then amplified by PCR 
and go through the selection process again, with more stringent measures [16].  
Figure 4. Cell-SELEX, with counter-selection done against negative cells. Taken from Guo et al. (2008).  
 Counter-selection serves to eliminate aptamer candidates that may bind to cells other than the 
target; thus, aptamers that bind less specifically. This has been shown to be especially useful in the field 
of cancer research. Researchers incubated the oligonucleotide library with a cultured precursor T cell 
acute lymphoblastic leukemia (ALL) cell line, called CCRF-CEM, while using a B-cell line from 
human Burkitt's lymphoma called Ramos as the counter-selection [16]. This allowed the researchers to 
select for aptamers that bound much more specifically to CCRF-CEM as opposed to the Ramos cells, 
which shares several cell surface ligands. In this way, aptamers can be very useful in discovering 
cancer-specific bio-markers and cell-surface epitopes, which would allow physicians to target and 
destroy cancer cells specifically, as opposed to current treatments that put somatic cells (that are similar 
to the cancer cells) at risk [16][17][18]. Aptamers have also shown great potential in early cancer 
detection. Current methods that attempt to detect specific types of cancer lines have been met with 
great difficulty due to a low density of cell surface targets for binding. Aptamers conjugated with 
nanoparticles such as Au-Ag nanorods show much greater efficacy in binding to the cancer cells 
specifically, as the aptamer-nanorod complexes did not bind to non-target cells [16]. Aptamers can also 
be conjugated with magnetic and fluorescent nanoparticles (MNP and FNP, respectively), which makes 
it even easier to detect and diagnose the presence of the target cells. These bioconjugates have the 
potential to greatly aid drug delivery, as current chemotherapies often result in death of both healthy 
and cancerous cells [17]. Lastly, aptamers are useful in biological system not only because of their 
specific binding (which reduces the chance of side effect toxicity), but also because they have relatively 
short half-lives (due to organic nuclease activity) and are quickly cleared out of the bloodstream by 
kidneys. Certain modifications such as polyethylene glycol linkage can increase the half-live up to a 
week [17]. 
 In our research, we expect to develop an aptamer that binds specifically to the hFSHR in vitro 
using a modified version of the standard cell-SELEX procedure. We will perform the counter-selection 
first, using human embryonic kidney cells (HEK293) provided by James A. Dias from the University of 
Albany. We will then discard the cells and their bound aptamers, and collect the remaining unbound 
oligonucleotides and incubate them with hFSHR-transfected HEK293 cells (henceforth referred to as 
HEK293r's). These oligonucleotides will only bind the FSHR, as they have already been counter-
selected against the other ligands present on the HEK293r cells. Afterward, the bound oligonucleotides 
will be eluted and amplified and subject to more rounds of selections, with increasing stringency. 
 Producing aptamers that bind very specifically to the hFSHR will inhibit the natural hormone 
from binding, which we hypothesize will stunt follicular development, thus acting as a form of oral 
contraception, most likely for males. . This is a novel project that will open the door to a new, safer and 
possibly more cost-effective form of contraception that does not introduce extra hormones into the 
human body. It also holds potential as a sterilization method for cats and dogs, which would reduce 
euthanasia rates in pet shelters. 
Materials and Methods 
 
RNA pool. We purchased our pool of random oligonucleotides from Integrated DNA Technologies, Inc. 
The total pool contained 100 nmol of ssDNA, which we aliquoted and diluted to several samples that 
????????????????????????????????????????????????????????????????????was 77 bases in length, with a 
randomized 40 base region in the center. The outer 5' and 3' regions were kept constant in order to bind 
to T7-XbaI and Rev-HinDIII flanking PCR primers, respectively. The sequence for our primers and 
oligonucleotide were obtained from Bouvet's protocol, and are shown below [17]:  
Table 2. The sequences for both primers and oligonucleotide molecules we used.  
Nucleic acid strand Sequence 
T7-XbaI flanking primer 3’-TTA CAG CAA CCA CCG GG GAT ATC ACT CAG CAT AAT CCT AGG CGC-5’ 
Rev-HinDIII flanking primer 5’-CCC GAC ACC CGC GGA TCC ATG GGC ACT ATT TAT ATC AAC-3' 
Oligonucleotide 5'-TGGGCACTATTTATATCAAC(N40)AATGTCGTTGGTGGCCC-3' 
 
After PCR amplification, we converted our dsDNA pool into an ssRNA pool via transcription. 
 
PCR?????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????l 
cycling began with one cycle at 95°C for one minute , 25 repeating cycles at 94°C for one minute, 50°C 
for one minute, and 72°C for one minute, followed by a cycle at 72°C for ten minutes. After PCR, the 
presence of product was confirmed by 3% agarose ge??????????????????????????????????????????
subsequently purified by phenol/chloroform extraction and ethanol precipitation.  
 
Cell-SELEX. 135-??????????????????????????????????????????????? ???????????????????????????????????
ice. Afterward, they were incubated with HEK-293 cells with transfected hFSHR (or with untransfected 
cells if counter-selection was being performed) for 45 minutes at different temperatures (starting at 
4°C) depending on stringency level. At room temperature and above, RNAse inhibitor was also 
employed. Cells were vigorously vortexed and triterated to increase surface area for receptor binding. 1 
mL of binding buffer was also added. After selection, centrifugation was done at 13,000 RPM for five 
minutes and the supernatant was discarded. ????????????????????????????????????????????????????????
and heated again at 95°C for five minutes to elute the bound oligonuceotides. Centrifugation was then 
done once more under the same conditions, and the supernatant was collected and a phenol/chloroform 
extraction was performed. Afterward, reverse transcription and PCR amplification were done to 
ascertain the presence of product. 
 
Wash buffer and binding buffer. The wash buffer solution was composed of 450 mg glucose, 10 mL 10x 
PBS buffer, 5 mM MgCl2 and 90 mL of nanopure water. The binding buffer was created using 10 mL 
of wash buffer and 10 mg of Bovine Serum Albumin (BSA).  
 
Transcription and reverse transcription. Transcription was done using a HiScribeTM T7 in vitro 
transcription kit, specifically: ??????????????????????????????????????????????????????? ????????????
???????????????????????????????????????????-Fluoro-???????????????-Fluoro-UTP from TriLink 
??????????????????????????????? ?????????????????????? ??????????????????????????????? 
Reverse transcription was done using a Quanta Biosciences, Inc. qScriptTM cDNA synthesis kit, 
??????????????????????????????????????????-????????????????? ??????????????????????????????????
????????????????????????????????????????????????????? 
Results 
For the counter-selection, the random oligonucleotide pool was incubated with wild-type HEK-293 
cells. The supernatant RNA was then enriched via reverse transcription and PCR, and a band estimated 
to be about 123 base pairs was obtained, as shown in lane 2 (Figure 5a), indicating a successful 
recovery of RNA that did not bind to the wild-type cells. This band presented itself again after the first 
round of positive selection with HEK-293R cells, which also occurred at 4oC (Figure 5b), representing 
the fraction of our oligonucleotide pool that binds to the FSHR containing cells at 4oC. This band, 
however, was absent in the gel after the second round of selection (at 22oC), as shown in Figures 5c and 
5d. Only after the addition of an RNAse inhibitor did this band appear again (Figure 5e), which 
indicates that RNA was now being successfully eluted from FSHR proteins at 22oC.  
 The nanodrop experiment (Figure 6) done on this current oligonucleotide pool showed that 
there was a concentration of 55.2 ng/uL of RNA suspended in the solution. The nanodrop experiments 
(Figures 7 and 8) done on both RNA incubated with both normal type HEK293 cells  and FSHR 
transfected HEK-293 cells yielded concentrations of 154.1 ng/uL and 100.8 ng/uL, respectively.  
 Selection was carried out at 30oC, but the 135 base pair band was absent again (Figure 5f), even 
with the addition of the RNAse inhibitor. 
 
 
 
 
Figure 5. Gels showing results after counter-selection (5a), SELEX at 4oC (5b), SELEX at 22oC (5c-e), and SELEX at 30oC 
(5f). DNA molecular weight markers are in the first lane, and the product band in the second lane. 
 
Figure 6. Nanodrop experiment showing the absorbance of RNA at 230 nanometers (nm) for the oligonucleotide pool. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Nanodrop experiment showing the absorbance of RNA at 230 nanometers (nm) for the HEK-293 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Nanodrop experiment showing the absorbance of RNA at 230 nanometers (nm) for the HEK-293r cells. 
 
Discussion 
 
Using Cell-SELEX, we have been able to select for a group of oligonucleotides that bind to the hFSHR 
at room temperature. The presence of these oligonucleotides has been determined by both gel 
electrophoresis of the PCR product after reverse transcription of our RNA and by the nanodrop 
experiment. The latter shows a lower concentration of RNA when incubated with the HEK-293r cells, 
indicating that some portion of the oligonucleotides are binding effectively to the FSH receptor, though 
more experimentation needs to be done to quantify the level of binding.  
 Each RNA molecule in our current pool is 123 bases long, though we started from a pool in 
which the the oligonucleotides were 77 bases long (consisting of two flanking constant regions for 
primer binding during PCR that are 17 (3' end) and 20 (5' end) bases each and a middle randomized 40 
base region). This increase in RNA molecule length is due to the nature of the flanking primers we 
used, as according to Bouvet's protocol [19]: the T7 flanking primer, binding to the 3' end of our 
oligonucleotides, is 39 bases long, and the Rev flanking primer, binding to the 5' end, is 44 bases long, 
as can be seen in Table 2. After PCR amplification, this results in an RNA oligonucleotide pool that is 
46 bases longer than the original pool.  
 Longer constant regions may encourage new, stronger forms of binding, as the molecules have 
more opportunity for different forms of 3-dimensional binding, such as larger stem loops or three way 
junctions. However, the fact that primers are longer than the constant regions of the parent 
oligonucleotides mean that there are several nucleotides on both primers that do not bind predictably to 
any present sequence (19 and 27 on the T7 and Rev flanking primers, respectively). There is a  
possibility that parts of these 'extra' sequences may bind to parts of the randomized 40-mer region, 
masking that sequence's accessibility to binding to the FSHR. This may result in the loss of some 
potential aptamer candidates. 
 The actual values for the concentration of RNA for the nanodrop experiments are also important 
to address. Incubating the oligonucleotides with wild-type HEK293 cells showed a concentration of 
RNA that was 53.2 ng/uL greater than that of the RNA incubating with HEK293r cells, which shows 
some degree of specific binding to hFSHR. However, both concentrations are over 100 ng/uL, a 
seemingly impossible value when we consider that the nanodrop experiment of just our RNA pool 
showed a concentration of 55.2 ng/uL. We expected that the nanodrop of the RNA incubating with the 
wild type HEK293 cells would have showed a concentration equal to or slightly less than that of the 
nanodrop experiment of the RNA pool (as some of the oligonucleotides may still be binding to the 
molecules on the surface of the HEK293 cells). As for the RNA incubating with HEK293r cells, we 
expected a lower concentration than 55.2 ng/uL, if they were binding more specifically to the 
transfected hFSHR proteins.  
 We can begin to explain this paradoxical situation by using the simple fact that HEK293 have 
their own native RNA molecules. The cells would have been somewhat lysed from the beginning of the 
incubation due to the method of storage. Being frozen in water and stored in a -20oC freezer would 
cause ice crystals to form and puncture the cells. Next, to thoroughly incubate the cells with the RNA 
pool in a way that increased potential receptor-oligonucleotide interaction, the cells were triterated and 
vortexed, causing further strain and breakage. This will lead to the cell's native RNA's to be expelled 
into the solution that contains our aptamer candidates. The nanodrop machine cannot distinguish 
between the two different groups of RNA and this likely resulted in the much larger reported 
concentration of RNA than expected.  
 In the future, this part of our research can be improved by changing the procedure by which the 
nanodrop experiment is done: instead of using deionized water as the control, we should use the 
solution surrounding HEK293 cells. In other words, in addition to incubating the RNA pool with 
HEK293 and HEK293r cells, a third tube should have only HEK293 without our oligonucleotide 
molecules present. All other treatments should remain the same: the cells will be triterated and vortexed 
and left at room temperature for 45 minutes. Theoretically, the native RNA molecules will come out 
just the same. If this solution were used as the control, the HEK293's RNA should be subtracted out 
when the nanodrop experiment is done on the other two solutions, and our aptamer candidates should 
be the only RNA molecules for which the nanodrop experiment reports the concentration. 
 In addition to the native RNA, riboncleases (RNAses) are released upon cell lysis. These 
molecules are used by all organisms to catalyze RNA degradation, a process that is crucial if the parent 
RNA is no longer required or if the smaller metabolites are to be used in new molecular pathways [20].   
There are many types of RNAses, some of which are not particularly specific. This helps the cell target 
foreign RNA molecules, such as viral injected RNA, and inactivate them.  
 This situation presented itself as a problem in our experiment: our aptamer candidates are 
essentially foreign RNA molecules. At 22oC, we could not recover our RNA molecules after the 
SELEX process, and it is most likely due to the presence of RNAse molecules that emerged from the 
lysed HEK293 cells (Figures 5c and 5d). We put this hypothesis to the test by running another SELEX 
experiment at 22oC, this time adding an RNAse inhibitor, a molecule that binds to RNAse molecules in 
order to prevent RNA degradation. As can be seen in Figure 5e, this allowed us to recover 
oligonucleotides after the SELEX process. At 4oC, the SELEX process went to completion, even 
without the use of the RNAse inhibitor [Figure 5b]. The lower temperature neatly explains this 
phenomenon: most enzymes, such as ribonucleases, are active at certain temperature ranges, and 4oC is 
too low for activation of RNAses. 
 However, even with the presence of the inhibitor, the SELEX did not work at 30oC;  The 
expected 134 base pair band was absent from the subsequent gel (Figure 5f). As all other conditions in 
this experimental run were identical to that in the 22oC run, the change in temperature must be the main 
factor that is contributing to the loss of product. Logically, there are three major ways the increased 
temperature may affect the experiment: it may be reducing the efficacy of the RNAse inhibitor, it may 
be affecting the structure of the oligonucleotides, or it may be inhibiting the binding between the RNA 
molecules and the hFSHR protein. 
 The RNAse inhibitor that we used was a 50 kDa water-soluble protein derived from rat lung, 
whose recombinant product is produced in E. coli (Roche®) [21]. At higher temperatures, proteins will 
begin to denature and lose their specific tertiary structure, which leads to inhibition or loss of regular 
function. Our RNAse inhibitor protein is reported to have an active temperature range of 25°C – 55°C, 
and still retain partial activity at 60°C [21]. Our last SELEX procedure was done at 30°C, which is well 
within the active temperature range for our inhibitor, thus eliminating the possibility of enzyme 
degradation as an explanation for the lack of binding oligonucleotides. 
 Our RNA molecules form specific three-dimensional shapes via both Watson-Crick and non-
standard hydrogen bonding (such as Hoogstein base pairing) between the bases on its own sequence. 
Heat definitely affects the strength of this binding, as melting curves have been analyzed for both RNA 
and DNA, in order to the determine the point at which the hydrogen bonds break and the sequence 
denatures. These studies cast doubt on the idea that increasing the temperature of our SELEX  
procedure from 22°C to 30°C is causing changes in the structures of our RNA oligonucleotides, as  
30°C is not a high enough temperature to truly affect the strength of base pairing. Research done has 
shown that tRNA, which is similar to our aptamer candidates in that it is a single stranded RNA chain 
base paired to itself, have melting ranges between 50oC and 75oC, depending on various factors, such 
as: ion concentrations, GC content, length of the RNA sequence and specific 3-dimensional structure 
(number, size and length of loops) [22][23]. At some point in the melting curve, there is usually a 
sudden, sharp increase in denatured RNA. This sharp slope indicates that there is a fast transition 
between between stable and denatured RNA, and that the heat is not slowly altering the 3-dimensional 
structure throughout the process. Also, tRNA molecules are generally between 70-95 bases long, and 
our oligonucleotides are 134 bases long; a longer chain leads to more stability through an increased 
number of hydrogen bonding[22]. So it may be concluded that our SELEX at 30°C is not altering the 
actual structure of the oligonucleotides. 
 Receptor-drug interactions are sensitive to small changes in the environment, such as pH, 
solubility, and temperature. Another possibility for the lack of binding in our latest SELEX may be that 
increasing the temperature from 22°C to 30°C is affecting the binding of our oligonucleotides to the 
hFSHR binding site in some unfavorable way. However, the hFSHR binds to its natural ligand, FSH, at 
human body temperature, which is 37°C. We have shown experimentally that our oligonucleotides bind 
at 22°C, so it seems unlikely that the binding interaction would be stunted at 30°C but then at 37°C, 
occur readily. One explanation is that our RNA molecules bind less strongly to the active site than the 
natural ligand. Experimentation must be done to ascertain the binding strengths of our current 
oligonucleotides to the hFSHR and compare it to that between FSH and the hFSHR.  
 Additionally, it is possible that our oligonucleotides are not binding to the active site at all; 
perhaps they are binding allosterically, or as an umbrella agonist/antagonist [24]. That is also a question 
that remains to be answered: we do not know the exact nature of the oligonucleotide-protein binding. 
There are many facets to consider: agonism versus antagonism of the hFSHR, the strength of binding (a 
partial antagonist may end up competing with FSH in binding to the receptor) and the location of 
interaction. Our RNA molecules may be binding allosterically or as umbrella agonist/antagonist.  
 After we succeed in using our cell-SELEX procedure to produce a pool of RNA that binds 
effectively at 37°C, the next course of action will be to quantitatively determine the strength and nature 
of binding. We will also need to determine the exact sequences of our best aptamers. Our long term 
future goals are to start in vivo trials of our aptamers in models model organisms whose FSH receptor 
protein is best conserved as compared to humans. Eventually, we can begin a SELEX process 
specifically for cat or dog FSHR (or other important reproductive proteins). At present, there are still 
many questions that need to be answered, and much research needs to be done. 
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